AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01352689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828(FDC)
Description: Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
Study NCT01352689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Therapy
Description: Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily
Study NCT02552563 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dementia Care Management
Description: The intervention involves two main components. The first component includes individualized dementia care management that involves regular and extended contact between the CG, care manager, and when appropriate, Veteran's primary care provider (PCP). The care manager monitors Veterans' symptoms via CG report, provides psychoeducation and support to CGs, influences adherence to guidelines by providing timely and tailored information to PCPs, and suggests appropriate care strategies and service referrals. The second major component is the Telehealth Education Program (TEP). For this pilot study, the program was modified for use with individual CGs and was formatted so that CGs could select from a menu of up to 7 modules covering various content areas evaluated during the course of the care management assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, long-term planning, etc.).
Study NCT00429273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine
Description: Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures
Study NCT00429273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures
Study NCT00429273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate (MPH)
Description: Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.
Study NCT00429273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Description: Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.
Study NCT03211689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Participants will utilize the Physitrack exercise program to engage in up to 150 minutes of exercise at a rating of 11-14 on the Borg Rate of Perceived Exertion scale, per week.
Study NCT03773679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Daily Exercise
Description: Daily Exercise Programme
Study NCT01955434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO
Study NCT03921086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Antihypertensive medication according to the study's algorithm
Description: Patients with stage 1 hypertension will receive monotherapy and risks of hypotension are negligible. A single antihypertensive lowers blood pressure (BP) on average by 10/5 mmHg.~Patients with stage 2 hypertension will be initiated on two medications and this is recommended by all international hypertension guidelines and studies have shown prompt BP control with minimal side effects.~For borderline patients, the investigators will elect to not treat them for blood pressure ranges of BP: 135-140/85-90 mmHg and give them a letter on discharge to be followed up at their local clinic. The letter will detail that they are potentially hypertensive patients and need to be followed up closely in future.~Patients with Stage 3 hypertension will be referred to the in-hospital physician as per the algorithm.
Study NCT02599272 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rice with tomatoes and peeled aubergine (no spice)
Description: Dose 0
Study NCT02599272 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice with vegetables and low spice
Description: Dose 1, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, peeled aubergine, onion, ginger and garlic
Study NCT02599272 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice with vegetables and high spice
Description: Dose 2, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, onion, ginger and garlic
Study NCT03398395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endocrown restoration
Description: a cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
Study NCT03398395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 90° shoulder endocrown restoration
Description: a 90°cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
Study NCT01955434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01438957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride
Description: Dexmedetomidine 0.2 to 0.7 mcg/kg/hr
Study NCT01955434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01955434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01955434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smac Mimetic LCL161
Description: Given PO
Study NCT00394901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, oral administration for 13 weeks (1 week titration and 12-week fixed dose).
Study NCT00394901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 150mg/day (75mg BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
Study NCT00394901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 300mg/day (150mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
Study NCT00394901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 600 mg/day (300 mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
Study NCT01438957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02634684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextroamphetamine
Description: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
Study NCT03697499 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: fish oil and acute ozone exposure
Description: The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
Study NCT03697499 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: fish oil and sham exposure
Description: The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
Study NCT03697499 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: soy oil and acute ozone exposure
Description: The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
Study NCT03697499 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: soy oil and sham exposure
Description: The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation
Study NCT01209455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorphenamine and Ranitidine
Description: We intend to use chlorphenamine (H1 antagonist) and ranitidine (H2 antagonist).Assuming NAC causes vasodilatation with an increase in forearm blood flow, we propose to administer 5 mcg/min to ensure maximal H1 blockade. In the presence of increased forearm blood flow, we propose to administer 37.5 mcg/min.
Study NCT01209455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Therapeutic IV administration of 1g paracetamol results in a plasma concentration of \~12 mg/l. To achieve a desired concentration of \~25 mg/l, in the presence of a forearm blood blow of 50 ml/min, we would intend to administer an IA infusion of 1.25 mg/min. To account for the presence of increased forearm blood flow, we propose to administer 4 mg/min IA paracetamol.
Study NCT01209455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: To achieve a local paracetamol concentration of \~200 mg/l, a concentration comparable to potentially hepatotoxic concentrations following paracetamol overdose, we propose to administer 30 mg/min paracetamol.
Study NCT04070326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Participants will receive 150 mg dose of lanadelumab every 2 or 4 weeks, depending on the participants age, over the 52-week treatment period.
Study NCT01886690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxymethylcellulose sodium based new eye drop formulation
Description: 1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
Study NCT01886690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboxymethylcellulose sodium based eye drops
Description: 1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
Study NCT02634684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextroamphetamine
Description: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
Study NCT02634684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
Study NCT02634684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
Study NCT04850131 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Desarda repair
Description: Desarda is a new tissue-based technique developed from applying the externally oblique muscle aponeurosis in the form of an undetached strip making the posterior wall in the inguinal canal stiffer. This paper focuses on analyzing comparisons between mesh-free Desarda repair and the Lichtenstein technique for the treatment of hernia inguinalis
Study NCT02845544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates-based exercises
Study NCT02630550 — intervention group
Intervention type: DEVICE
Intervention: Cheetah NICOM
Description: The Cheetah NICOM will be installed on all patients to evaluate the validity of its measurements.
Study NCT02630550 — intervention group
Intervention type: DEVICE
Intervention: Transesophageal echocardiography (TEE)
Description: TEE will serve as gold standard measurements for the evaluation of the Cheetah NICOM.
Study NCT02653391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A Elamipretide 1.0% Ophthalmic Solution
Description: Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye.
Study NCT02653391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B Elamipretide 3.0% Ophthalmic Solution
Description: Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both eyes.
Study NCT02653391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A Placebo
Description: Part A Each subject will receive one drop of vehicle ophthalmic solution BID in the paired eye of the randomly selected study eye.
Study NCT02653391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part B Placebo
Description: Part B: Each subject will receive one drop of vehicle ophthalmic solution BID in both eyes.
Study NCT01938599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM001 Cream, 7.5%
Description: Cream, 2x daily for 12 weeks
Study NCT01938599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of AM001 Cream
Description: Cream, 2x daily for 12 weeks
Study NCT03836612 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observation of routine clinical practice
Study NCT00948623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity counseling program
Study NCT00948623 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham counseling program
Study NCT01793675 — intervention group
Intervention type: PROCEDURE
Intervention: transplant with haploidentical donor
Description: patients with advanced MDS without identical sibling donor receive haploidentical transplant
Study NCT03280914 — intervention group
Intervention type: DEVICE
Intervention: Auto-CPAP
Description: Automatic Continuous Positive Airway Pressure treatment is the first-line treatment of obstructive sleep apnea
Study NCT03645980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 300 mg
Description: DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
Study NCT03645980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 600 mg
Description: DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
Study NCT03645980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: For combination with DKN-01, sorafenib will be administrated according to standard clinical practice. Part A: After 8 weeks monotherapy with DKN-01, the study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. Part B:After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
Study NCT00132145 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Vascular Management Program
Study NCT00132145 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinical Care Coordinators
Study NCT00132145 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Web-based Vascular Tracker for Patient and Physician
Study NCT00132145 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Automated Telephone Reminder System
Study NCT03590145 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical examination
Description: Standardized clinical examination consisting of pain provocation test, including palpation, muscle resistance and stretch test.
Study NCT04502953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertical plication
Description: Vertical plication of the rectovaginal septum was done
Study NCT04502953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Horizontal plication
Description: Horizontal plication of the rectovaginal septum was done
Study NCT01693926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute physical activity intervention
Description: 25 min of physical activity. The placebo arm will have 25 min of reading.
Study NCT01693926 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04316754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: music
Description: During angiography, the Intervention-1 group will listen to the music that the child wants to listen to. The Intervention-2 group will listen to the Arts of Fugue by Bach. No music will be played to the control group.
Study NCT03080545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar 0.005%-0.064% Topical Foam
Description: Topical foam
Study NCT01410409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular training (NEMEX-TJR)
Description: 60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
Study NCT00658593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Study NCT00658593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Study NCT00658593 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study NCT02044601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle.~Phase II: Maximum tolerated dose from Phase I.
Study NCT02044601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Phase I and II: 150 mg by mouth every day throughout radiation, except for chemotherapy day.
Study NCT02044601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Phase I and II: 45 mg/m2 by vein once a week throughout radiation for 7 weeks.
Study NCT02044601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Phase I and II: AUC 2 by vein once a week throughout radiation for 7 weeks.
Study NCT02044601 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Phase I and II: Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.
Study NCT01550380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: NVP-BKM120 (BKM120) is an oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor belonging to the 2,6-dimorpholino pyrimidine derivative family.Supplied in 10mg or 50mg capsules. Starting dose: 100mg Once Daily
Study NCT03838133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC590
Description: TLC590, a sustained-release formulation of the local anesthetics with lipid-based excipients
Study NCT03838133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naropin®
Description: Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. 50 mg (0.5%, 10 mL)
Study NCT03838133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline (0.9% sodium chloride, 10ml)
Study NCT03838133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 50 mg (0.5%, 10 mL)
Study NCT01918761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib, Pemetrexed
Description: Pemetrexed 500mg/m2 i.v (q21d) Dacomitinib 45mg orally (continuous)
Study NCT02436889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Study NCT02436889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine Tartrate
Study NCT02725593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg tablets administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, for the 28-week site and subject blinded long term extension.
Study NCT02725593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin placebo
Description: matching placebo tablets, administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily,for the 28-week site and subject blinded long term extension.
Study NCT01244633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam
Description: 50 or 100 mg tablets given once per day for eight weeks